Riskpilot← Back to searchSign inGet full accessArex Intressenter AB
ABActiveOrg 5592354913Klarabergsviadukten 70Business and other management consultancy activities · NACE 7020Est. 20201-4 employees
Revenue 2024
SEK 7M
+5% vs 2023
EBITDA margin
49.1%
+29% vs 2023
Equity ratio
33.8%
Financial strength
Net profit 2024
SEK 4,2M
-35% vs 2023
| Revenue | SEK 7M | +5% |
| EBITDA | SEK 3,4M | +29% |
| Net profit | SEK 4,2M | -35% |
| Total assets | SEK 13,9M | -15% |
| Equity | SEK 4,7M | -28% |
| Employees | — | — |
Legal name
Arex Intressenter AB
Org number
5592354913
Legal form
Aktiebolag
NACE code
7020 · Business and other management consultancy activities
Founded
7 januari 2020
Share capital
SEK 25 000
Employees
1-4
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av Thunell, Carl Staffan Thunell, Linda Birgitta
Company purpose
Bolaget ska, direkt eller via dotterbolag, tillhandahålla konsulttjänster till läkemedels-, medicinteknik- och hälsovårdsindustrin, samt därmed förenlig verksamhet.
Address
Klarabergsviadukten 70
Email
staffan.thunell@arexadvisor.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 1 819 | 6 048 | 6 290 | 6 636 | 6 968 |
| Staff expenses | — | — | −3 810 | — | −3 433 |
| EBITDA | −47 | 2 315 | 2 425 | 2 659 | 3 418 |
| Depreciation & amort. | −0 | −0 | — | −0 | — |
| EBIT | −47 | 2 315 | 2 425 | 2 659 | 3 418 |
| Net financials | — | — | 4 044 | 4 278 | 1 461 |
| Profit before tax | −47 | 2 315 | 6 470 | 6 936 | 4 880 |
| Tax | −0 | −469 | −500 | −471 | −656 |
| Net profit | −47 | 1 846 | 5 970 | 6 465 | 4 224 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 6 696 | 10 279 | 14 694 | 16 455 | 13 940 |
| Equity | 78 | 1 924 | 6 094 | 6 559 | 4 714 |
| Long-term debt | 5 990 | 6 890 | 6 890 | 6 006 | 4 394 |
| Short-term debt | 628 | 1 465 | 1 711 | 3 891 | 4 833 |
| Total debt | 6 618 | 8 355 | 8 601 | 9 897 | 9 227 |
EBITDA margin
49.1%
This company
15.8%
Market median
+211% vs market
20202024
Equity ratio
33.8%
This company
38.2%
Market median
+12% vs market
20202024
Return on equity
89.6%
This company
18.4%
Market median
+387% vs market
20202024
Net profit margin
60.6%
This company
8.1%
Market median
+648% vs market
20202024
Asset turnover
0.50×
This company
1.12×
Market median
-55% vs market
20202024
Debt / equity
1.96×
This company
0.62×
Market median
-216% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
LB Chief Executive Officer | Chief Executive Officer | 2021 | — | — |
EA Chief Auditor | Chief Auditor | 2021 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2021 | — | — | |
| Chairman | 2021 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Nevada Pharma AB | Company | 60.0% | 60.0% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Nevada Pharma AB
Arex Intressenter AB Board members of Arex Intressenter AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Linda Birgitta Thunell | Chief Executive Officer | 0 companies |
| Erik Adrian Emilsson | Chief Auditor | 0 companies |
| Erik Thomas Hedner | Board of Directors | 0 companies |
| Eva Lovisa Kristina Rosenquist | Board of Directors | 0 companies |
| Carl Staffan Thunell | Chairman | 0 companies |